Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leritrelvir Pharmacokinetics and DDI Study
NCT06031454Phase 1Completed
- Sponsor
- Raynovent Biotech
- Start
- Sep 2023
- Primary completion
- Nov 2023
- Modality
- Covalent Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of leritrelvir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Raynovent Biotech. Primary endpoints: Maximum Plasma Concentration (Cmax) and Area Under the Curve (AUC). Started Sep 2023; status: completed.
02
Drugs
leritrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06031454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06031454.